Spots Global Cancer Trial Database for CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Official Title: Phase II Open-Label, Multi-Center Study of CP-547, 632, an Oral Tyrosine Kinase Inhibitor of VEGFR-2, in Subjects With Recurrent or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, or Fallopian Tube Cancer

Study ID: NCT00096239

Conditions

Fallopian Tube Cancer

Ovarian Cancer

Primary Peritoneal Cavity Cancer

Interventions

CP-547,632

Study Description

Brief Summary: RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well CP-547,632 works in treating patients with recurrent or persistent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Detailed Description: OBJECTIVES: Primary * Determine the efficacy of CP-547,632, in terms of clinical response benefit (CA 125 response \[complete response (CR) or partial response (PR)\] or stable disease ≥ 16 weeks), in patients with recurrent or persistent small-volume ovarian epithelial, primary peritoneal serous, or fallopian tube cancer. Secondary * Determine progression-free survival of patients treated with this drug. * Determine CA 125 response (CR or PR) rate in patients treated with this drug. * Determine duration of CA 125 response in patients treated with this drug. * Determine the safety of this drug in these patients. * Correlate the steady state plasma concentration of this drug with efficacy and toxicity in these patients. * Correlate clinical outcome with an angiogenic profile derived from measurement of serum vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8 in patients treated with this drug. * Determine changes in the Hospital Anxiety and Depression Scale (HADS) in patients treated with this drug. OUTLINE: This is an open-label, multicenter study. Patients receive oral CP-547,632 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 30 days and then every 3 months for 2 years. PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 1 year.